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Background
Antibody therapeutics targeting the Immune Modulatory
Receptor (IMR) PD-1 have efficacy in multiple indications,
and molecules targeting other IMRs are in development.
Increased understanding of IMR biology is required to
design rational combination therapies and identify biomar-
kers of response and toxicity. Here we applied Single Cell
Network Profiling (SCNP) to assess functional signaling
across immune cell subsets in the context of IMR expres-
sion, using PBMC of CLL and healthy donors (HD).
Materials and methods
SCNP is a multiparametric flow cytometry-based technol-
ogy enabling simultaneous analysis of signaling networks
in primary human samples across immune cell subsets
without cell subset isolation. CLL (n=20) and HD (n=10)
PBMC were profiled to interrogate; a) expression patterns
of multiple IMRs (PD-1, PD-L1, OX-40, 4-1BB, GITR,
LAG-3, TIM3) across cell subsets including effector and
central memory (EM, CM) T cells, b) cell subset specific
signaling following modulation with IL-2, IL-10, IL-15, or
TCR (anti-CD3/anti-CD28), and c) the effects of PI3Kd or
BTK inhibitors. CLL and HD data were compared to iden-
tify dysfunctional IMR expression and signaling associated
with disease.
Results
IMR expression across HD was similar whereas expression
was heterogeneous in CLL. PD-1 expression was elevated
in CLL blasts and across all CLL T cell subsets including
effector and naïve T cells. In contrast, PD-1 was expressed
primarily in EM and CM T cells in HD samples. PD-L1
expression also was elevated in CLL blasts vs. HD B cells.
Reduced TCR à p-ERK and p-Akt was observed in a CLL
donor subgroup vs HD. Lower T cell signaling was not
associated with increased PD-1 expression but trended
with reduced TIM-3 expression. Contrasting with reduced
TCR responsiveness, increased IL-2 àp-Stat5 was observed
in CD8+ T cells in CLL. Cell signaling in the context of
PD-1 expression identified functional differences in CLL.
TCR signaling was uniformly reduced in HD PD-1+ vs
PD-1-T cells, whereas this trend was not consistent in
CLL. Inhibition of BTK resulted in specific reduction of
TCRàp-S6 but not p-AKT response, whereas PI3Kd inhi-
bition resulted in complete pathway coverage.
Conclusion
These data highlight how applying SCNP to profile both
IMR expression patterns and functional signaling across
immune cell subsets can be applied to immuno-oncology
drug development. Applications include interrogating
disease mechanism, informing rational combination
therapies and identifying patient subgroups that may
benefit from these therapies.
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